Last reviewed · How we verify
Chemotherapy arm B
Chemotherapy arm B is a Chemotherapy Small molecule drug developed by Prof. Dr. med. Claus Rödel. It is currently in Phase 2 development for Metastatic cancer. Also known as: all brands of Oxaliplatin are allowed, all brands of 5-fluorouracil (5-FU) are allowed, all brands of Folinic acid (FA) are allowed.
Chemotherapy arm B targets rapidly dividing cancer cells.
Chemotherapy arm B involves the use of Mitomycin C, a small molecule with a specific mechanism of action. This treatment is being studied in various clinical trials for conditions such as Pseudomyxoma Peritonei, Advanced Cancer, Mantle Cell Lymphoma, and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Chemotherapy arm B |
|---|---|
| Also known as | all brands of Oxaliplatin are allowed, all brands of 5-fluorouracil (5-FU) are allowed, all brands of Folinic acid (FA) are allowed |
| Sponsor | Prof. Dr. med. Claus Rödel |
| Drug class | Chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Chemotherapy agents in arm B work by interfering with DNA replication and cell division, ultimately leading to cell death. This mechanism is effective against a wide range of cancer types, but can also cause harm to healthy cells.
Approved indications
- Metastatic cancer
Common side effects
- Nausea
- Hair loss
- Fatigue
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Substance Misuse To Psychosis for Stimulants (PHASE2, PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotherapy arm B CI brief — competitive landscape report
- Chemotherapy arm B updates RSS · CI watch RSS
- Prof. Dr. med. Claus Rödel portfolio CI
Frequently asked questions about Chemotherapy arm B
What is Chemotherapy arm B?
How does Chemotherapy arm B work?
What is Chemotherapy arm B used for?
Who makes Chemotherapy arm B?
Is Chemotherapy arm B also known as anything else?
What drug class is Chemotherapy arm B in?
What development phase is Chemotherapy arm B in?
What are the side effects of Chemotherapy arm B?
Related
- Drug class: All Chemotherapy drugs
- Manufacturer: Prof. Dr. med. Claus Rödel — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic cancer
- Also known as: all brands of Oxaliplatin are allowed, all brands of 5-fluorouracil (5-FU) are allowed, all brands of Folinic acid (FA) are allowed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing